Medical Care
Global VEGF Targeted Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 04, 25
- ID: 530097
- Pages: 126
- Figures: 118
- Views: 3
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global VEGF Targeted Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical
Segment by Type
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other
Segment by Application
Hospitals
Clinics
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the VEGF Targeted Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global VEGF Targeted Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical
Segment by Type
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other
Segment by Application
Hospitals
Clinics
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the VEGF Targeted Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to VEGF Targeted Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global VEGF Targeted Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bevacizumab
1.2.3 Ramucirumab
1.2.4 Ranibizumab
1.2.5 Aflibercept
1.2.6 Conbercept
1.2.7 Other
1.3 Market Segmentation by Application
1.3.1 Global VEGF Targeted Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global VEGF Targeted Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global VEGF Targeted Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global VEGF Targeted Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global VEGF Targeted Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Bevacizumab Market Size by Players
3.3.2 Ramucirumab Market Size by Players
3.3.3 Ranibizumab Market Size by Players
3.3.4 Aflibercept Market Size by Players
3.3.5 Conbercept Market Size by Players
3.3.6 Other Market Size by Players
3.4 Global VEGF Targeted Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global VEGF Targeted Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global VEGF Targeted Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America VEGF Targeted Therapy Market Size by Type (2020-2031)
6.4 North America VEGF Targeted Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America VEGF Targeted Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe VEGF Targeted Therapy Market Size by Type (2020-2031)
7.4 Europe VEGF Targeted Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe VEGF Targeted Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific VEGF Targeted Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific VEGF Targeted Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific VEGF Targeted Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America VEGF Targeted Therapy Market Size by Type (2020-2031)
9.4 Central and South America VEGF Targeted Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America VEGF Targeted Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa VEGF Targeted Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa VEGF Targeted Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa VEGF Targeted Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche VEGF Targeted Therapy Product Features and Attributes
11.1.4 Roche VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Roche VEGF Targeted Therapy Revenue by Product in 2024
11.1.6 Roche VEGF Targeted Therapy Revenue by Application in 2024
11.1.7 Roche VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.1.8 Roche VEGF Targeted Therapy SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly VEGF Targeted Therapy Product Features and Attributes
11.2.4 Eli Lilly VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly VEGF Targeted Therapy Revenue by Product in 2024
11.2.6 Eli Lilly VEGF Targeted Therapy Revenue by Application in 2024
11.2.7 Eli Lilly VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.2.8 Eli Lilly VEGF Targeted Therapy SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Business Overview
11.3.3 Pfizer VEGF Targeted Therapy Product Features and Attributes
11.3.4 Pfizer VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Pfizer VEGF Targeted Therapy Revenue by Product in 2024
11.3.6 Pfizer VEGF Targeted Therapy Revenue by Application in 2024
11.3.7 Pfizer VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.3.8 Pfizer VEGF Targeted Therapy SWOT Analysis
11.3.9 Pfizer Recent Developments
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Corporation Information
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals VEGF Targeted Therapy Product Features and Attributes
11.4.4 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue by Product in 2024
11.4.6 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue by Application in 2024
11.4.7 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.4.8 Regeneron Pharmaceuticals VEGF Targeted Therapy SWOT Analysis
11.4.9 Regeneron Pharmaceuticals Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Business Overview
11.5.3 Novartis VEGF Targeted Therapy Product Features and Attributes
11.5.4 Novartis VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Novartis VEGF Targeted Therapy Revenue by Product in 2024
11.5.6 Novartis VEGF Targeted Therapy Revenue by Application in 2024
11.5.7 Novartis VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.5.8 Novartis VEGF Targeted Therapy SWOT Analysis
11.5.9 Novartis Recent Developments
11.6 Alphamab Oncology
11.6.1 Alphamab Oncology Corporation Information
11.6.2 Alphamab Oncology Business Overview
11.6.3 Alphamab Oncology VEGF Targeted Therapy Product Features and Attributes
11.6.4 Alphamab Oncology VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Alphamab Oncology Recent Developments
11.7 Chengdu Kanghong Pharmaceutical
11.7.1 Chengdu Kanghong Pharmaceutical Corporation Information
11.7.2 Chengdu Kanghong Pharmaceutical Business Overview
11.7.3 Chengdu Kanghong Pharmaceutical VEGF Targeted Therapy Product Features and Attributes
11.7.4 Chengdu Kanghong Pharmaceutical VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Chengdu Kanghong Pharmaceutical Recent Developments
12 VEGF Targeted TherapyIndustry Chain Analysis
12.1 VEGF Targeted Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 VEGF Targeted Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global VEGF Targeted Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to VEGF Targeted Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global VEGF Targeted Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bevacizumab
1.2.3 Ramucirumab
1.2.4 Ranibizumab
1.2.5 Aflibercept
1.2.6 Conbercept
1.2.7 Other
1.3 Market Segmentation by Application
1.3.1 Global VEGF Targeted Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global VEGF Targeted Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global VEGF Targeted Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global VEGF Targeted Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global VEGF Targeted Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Bevacizumab Market Size by Players
3.3.2 Ramucirumab Market Size by Players
3.3.3 Ranibizumab Market Size by Players
3.3.4 Aflibercept Market Size by Players
3.3.5 Conbercept Market Size by Players
3.3.6 Other Market Size by Players
3.4 Global VEGF Targeted Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global VEGF Targeted Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global VEGF Targeted Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America VEGF Targeted Therapy Market Size by Type (2020-2031)
6.4 North America VEGF Targeted Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America VEGF Targeted Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe VEGF Targeted Therapy Market Size by Type (2020-2031)
7.4 Europe VEGF Targeted Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe VEGF Targeted Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific VEGF Targeted Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific VEGF Targeted Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific VEGF Targeted Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America VEGF Targeted Therapy Market Size by Type (2020-2031)
9.4 Central and South America VEGF Targeted Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America VEGF Targeted Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa VEGF Targeted Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa VEGF Targeted Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa VEGF Targeted Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche VEGF Targeted Therapy Product Features and Attributes
11.1.4 Roche VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Roche VEGF Targeted Therapy Revenue by Product in 2024
11.1.6 Roche VEGF Targeted Therapy Revenue by Application in 2024
11.1.7 Roche VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.1.8 Roche VEGF Targeted Therapy SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly VEGF Targeted Therapy Product Features and Attributes
11.2.4 Eli Lilly VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly VEGF Targeted Therapy Revenue by Product in 2024
11.2.6 Eli Lilly VEGF Targeted Therapy Revenue by Application in 2024
11.2.7 Eli Lilly VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.2.8 Eli Lilly VEGF Targeted Therapy SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Business Overview
11.3.3 Pfizer VEGF Targeted Therapy Product Features and Attributes
11.3.4 Pfizer VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Pfizer VEGF Targeted Therapy Revenue by Product in 2024
11.3.6 Pfizer VEGF Targeted Therapy Revenue by Application in 2024
11.3.7 Pfizer VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.3.8 Pfizer VEGF Targeted Therapy SWOT Analysis
11.3.9 Pfizer Recent Developments
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Corporation Information
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals VEGF Targeted Therapy Product Features and Attributes
11.4.4 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue by Product in 2024
11.4.6 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue by Application in 2024
11.4.7 Regeneron Pharmaceuticals VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.4.8 Regeneron Pharmaceuticals VEGF Targeted Therapy SWOT Analysis
11.4.9 Regeneron Pharmaceuticals Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Business Overview
11.5.3 Novartis VEGF Targeted Therapy Product Features and Attributes
11.5.4 Novartis VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Novartis VEGF Targeted Therapy Revenue by Product in 2024
11.5.6 Novartis VEGF Targeted Therapy Revenue by Application in 2024
11.5.7 Novartis VEGF Targeted Therapy Revenue by Geographic Area in 2024
11.5.8 Novartis VEGF Targeted Therapy SWOT Analysis
11.5.9 Novartis Recent Developments
11.6 Alphamab Oncology
11.6.1 Alphamab Oncology Corporation Information
11.6.2 Alphamab Oncology Business Overview
11.6.3 Alphamab Oncology VEGF Targeted Therapy Product Features and Attributes
11.6.4 Alphamab Oncology VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Alphamab Oncology Recent Developments
11.7 Chengdu Kanghong Pharmaceutical
11.7.1 Chengdu Kanghong Pharmaceutical Corporation Information
11.7.2 Chengdu Kanghong Pharmaceutical Business Overview
11.7.3 Chengdu Kanghong Pharmaceutical VEGF Targeted Therapy Product Features and Attributes
11.7.4 Chengdu Kanghong Pharmaceutical VEGF Targeted Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Chengdu Kanghong Pharmaceutical Recent Developments
12 VEGF Targeted TherapyIndustry Chain Analysis
12.1 VEGF Targeted Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 VEGF Targeted Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global VEGF Targeted Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global VEGF Targeted Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global VEGF Targeted Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global VEGF Targeted Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global VEGF Targeted Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global VEGF Targeted Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global VEGF Targeted Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global VEGF Targeted Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Targeted Therapy as of 2024)
Table 11. Global VEGF Targeted Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global VEGF Targeted Therapy Companies Headquarters
Table 13. Global VEGF Targeted Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global VEGF Targeted Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global VEGF Targeted Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global VEGF Targeted Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global VEGF Targeted Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. VEGF Targeted Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America VEGF Targeted Therapy Growth Accelerators and Market Barriers
Table 25. North America VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe VEGF Targeted Therapy Growth Accelerators and Market Barriers
Table 27. Europe VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific VEGF Targeted Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America VEGF Targeted Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa VEGF Targeted Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche VEGF Targeted Therapy SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Eli Lilly Corporation Information
Table 44. Eli Lilly Description and Major Businesses
Table 45. Eli Lilly Product Features and Attributes
Table 46. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Eli Lilly Revenue Proportion by Product in 2024
Table 48. Eli Lilly Revenue Proportion by Application in 2024
Table 49. Eli Lilly Revenue Proportion by Geographic Area in 2024
Table 50. Eli Lilly VEGF Targeted Therapy SWOT Analysis
Table 51. Eli Lilly Recent Developments
Table 52. Pfizer Corporation Information
Table 53. Pfizer Description and Major Businesses
Table 54. Pfizer Product Features and Attributes
Table 55. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Pfizer Revenue Proportion by Product in 2024
Table 57. Pfizer Revenue Proportion by Application in 2024
Table 58. Pfizer Revenue Proportion by Geographic Area in 2024
Table 59. Pfizer VEGF Targeted Therapy SWOT Analysis
Table 60. Pfizer Recent Developments
Table 61. Regeneron Pharmaceuticals Corporation Information
Table 62. Regeneron Pharmaceuticals Description and Major Businesses
Table 63. Regeneron Pharmaceuticals Product Features and Attributes
Table 64. Regeneron Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Regeneron Pharmaceuticals Revenue Proportion by Product in 2024
Table 66. Regeneron Pharmaceuticals Revenue Proportion by Application in 2024
Table 67. Regeneron Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 68. Regeneron Pharmaceuticals VEGF Targeted Therapy SWOT Analysis
Table 69. Regeneron Pharmaceuticals Recent Developments
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Major Businesses
Table 72. Novartis Product Features and Attributes
Table 73. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Novartis Revenue Proportion by Product in 2024
Table 75. Novartis Revenue Proportion by Application in 2024
Table 76. Novartis Revenue Proportion by Geographic Area in 2024
Table 77. Novartis VEGF Targeted Therapy SWOT Analysis
Table 78. Novartis Recent Developments
Table 79. Alphamab Oncology Corporation Information
Table 80. Alphamab Oncology Description and Major Businesses
Table 81. Alphamab Oncology Product Features and Attributes
Table 82. Alphamab Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Alphamab Oncology Recent Developments
Table 84. Chengdu Kanghong Pharmaceutical Corporation Information
Table 85. Chengdu Kanghong Pharmaceutical Description and Major Businesses
Table 86. Chengdu Kanghong Pharmaceutical Product Features and Attributes
Table 87. Chengdu Kanghong Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Chengdu Kanghong Pharmaceutical Recent Developments
Table 89. Raw Materials Key Suppliers
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. VEGF Targeted Therapy Product Picture
Figure 2. Global VEGF Targeted Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Bevacizumab Product Picture
Figure 4. Ramucirumab Product Picture
Figure 5. Ranibizumab Product Picture
Figure 6. Aflibercept Product Picture
Figure 7. Conbercept Product Picture
Figure 8. Other Product Picture
Figure 9. Global VEGF Targeted Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. VEGF Targeted Therapy Report Years Considered
Figure 13. Global VEGF Targeted Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 15. Global VEGF Targeted Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global VEGF Targeted Therapy Revenue Market Share by Region (2020-2031)
Figure 17. Global VEGF Targeted Therapy Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Bevacizumab Revenue Market Share by Player in 2024
Figure 20. Ramucirumab Revenue Market Share by Player in 2024
Figure 21. Ranibizumab Revenue Market Share by Player in 2024
Figure 22. Aflibercept Revenue Market Share by Player in 2024
Figure 23. Conbercept Revenue Market Share by Player in 2024
Figure 24. Other Revenue Market Share by Player in 2024
Figure 25. Global VEGF Targeted Therapy Revenue Market Share by Type (2020-2031)
Figure 26. Global VEGF Targeted Therapy Revenue Market Share by Application (2020-2031)
Figure 27. North America VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 29. North America VEGF Targeted Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 31. US VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 32. Canada VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. Mexico VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Europe VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 35. Europe Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 36. Europe VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 37. Europe VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 38. Germany VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 39. France VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 40. U.K. VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. Italy VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. Russia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Top 8 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 45. Asia-Pacific VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 46. Asia-Pacific VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 47. Indonesia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Japan VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. South Korea VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Australia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. India VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. Indonesia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Vietnam VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 54. Malaysia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 55. Philippines VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 56. Singapore VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 57. Central and South America VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Central and South America Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 59. Central and South America VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 60. Central and South America VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 61. Brazil VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 62. Argentina VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Middle East and Africa VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Middle East and Africa Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 65. South America VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 66. Middle East and Africa VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 67. GCC Countries VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 68. Israel VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 69. Egypt VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 70. South Africa VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 71. VEGF Targeted Therapy Industry Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Table 1. Global VEGF Targeted Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global VEGF Targeted Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global VEGF Targeted Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global VEGF Targeted Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global VEGF Targeted Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global VEGF Targeted Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global VEGF Targeted Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Targeted Therapy as of 2024)
Table 11. Global VEGF Targeted Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global VEGF Targeted Therapy Companies Headquarters
Table 13. Global VEGF Targeted Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global VEGF Targeted Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global VEGF Targeted Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global VEGF Targeted Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global VEGF Targeted Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. VEGF Targeted Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America VEGF Targeted Therapy Growth Accelerators and Market Barriers
Table 25. North America VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe VEGF Targeted Therapy Growth Accelerators and Market Barriers
Table 27. Europe VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific VEGF Targeted Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America VEGF Targeted Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa VEGF Targeted Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa VEGF Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche VEGF Targeted Therapy SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Eli Lilly Corporation Information
Table 44. Eli Lilly Description and Major Businesses
Table 45. Eli Lilly Product Features and Attributes
Table 46. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Eli Lilly Revenue Proportion by Product in 2024
Table 48. Eli Lilly Revenue Proportion by Application in 2024
Table 49. Eli Lilly Revenue Proportion by Geographic Area in 2024
Table 50. Eli Lilly VEGF Targeted Therapy SWOT Analysis
Table 51. Eli Lilly Recent Developments
Table 52. Pfizer Corporation Information
Table 53. Pfizer Description and Major Businesses
Table 54. Pfizer Product Features and Attributes
Table 55. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Pfizer Revenue Proportion by Product in 2024
Table 57. Pfizer Revenue Proportion by Application in 2024
Table 58. Pfizer Revenue Proportion by Geographic Area in 2024
Table 59. Pfizer VEGF Targeted Therapy SWOT Analysis
Table 60. Pfizer Recent Developments
Table 61. Regeneron Pharmaceuticals Corporation Information
Table 62. Regeneron Pharmaceuticals Description and Major Businesses
Table 63. Regeneron Pharmaceuticals Product Features and Attributes
Table 64. Regeneron Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Regeneron Pharmaceuticals Revenue Proportion by Product in 2024
Table 66. Regeneron Pharmaceuticals Revenue Proportion by Application in 2024
Table 67. Regeneron Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 68. Regeneron Pharmaceuticals VEGF Targeted Therapy SWOT Analysis
Table 69. Regeneron Pharmaceuticals Recent Developments
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Major Businesses
Table 72. Novartis Product Features and Attributes
Table 73. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Novartis Revenue Proportion by Product in 2024
Table 75. Novartis Revenue Proportion by Application in 2024
Table 76. Novartis Revenue Proportion by Geographic Area in 2024
Table 77. Novartis VEGF Targeted Therapy SWOT Analysis
Table 78. Novartis Recent Developments
Table 79. Alphamab Oncology Corporation Information
Table 80. Alphamab Oncology Description and Major Businesses
Table 81. Alphamab Oncology Product Features and Attributes
Table 82. Alphamab Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Alphamab Oncology Recent Developments
Table 84. Chengdu Kanghong Pharmaceutical Corporation Information
Table 85. Chengdu Kanghong Pharmaceutical Description and Major Businesses
Table 86. Chengdu Kanghong Pharmaceutical Product Features and Attributes
Table 87. Chengdu Kanghong Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Chengdu Kanghong Pharmaceutical Recent Developments
Table 89. Raw Materials Key Suppliers
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. VEGF Targeted Therapy Product Picture
Figure 2. Global VEGF Targeted Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Bevacizumab Product Picture
Figure 4. Ramucirumab Product Picture
Figure 5. Ranibizumab Product Picture
Figure 6. Aflibercept Product Picture
Figure 7. Conbercept Product Picture
Figure 8. Other Product Picture
Figure 9. Global VEGF Targeted Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. VEGF Targeted Therapy Report Years Considered
Figure 13. Global VEGF Targeted Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 15. Global VEGF Targeted Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global VEGF Targeted Therapy Revenue Market Share by Region (2020-2031)
Figure 17. Global VEGF Targeted Therapy Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Bevacizumab Revenue Market Share by Player in 2024
Figure 20. Ramucirumab Revenue Market Share by Player in 2024
Figure 21. Ranibizumab Revenue Market Share by Player in 2024
Figure 22. Aflibercept Revenue Market Share by Player in 2024
Figure 23. Conbercept Revenue Market Share by Player in 2024
Figure 24. Other Revenue Market Share by Player in 2024
Figure 25. Global VEGF Targeted Therapy Revenue Market Share by Type (2020-2031)
Figure 26. Global VEGF Targeted Therapy Revenue Market Share by Application (2020-2031)
Figure 27. North America VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 29. North America VEGF Targeted Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 31. US VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 32. Canada VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. Mexico VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Europe VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 35. Europe Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 36. Europe VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 37. Europe VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 38. Germany VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 39. France VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 40. U.K. VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. Italy VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. Russia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Top 8 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 45. Asia-Pacific VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 46. Asia-Pacific VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 47. Indonesia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Japan VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. South Korea VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Australia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. India VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. Indonesia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Vietnam VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 54. Malaysia VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 55. Philippines VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 56. Singapore VEGF Targeted Therapy Revenue (2020-2031) & (US$ Million)
Figure 57. Central and South America VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Central and South America Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 59. Central and South America VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 60. Central and South America VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 61. Brazil VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 62. Argentina VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Middle East and Africa VEGF Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Middle East and Africa Top 5 Players VEGF Targeted Therapy Revenue (US$ Million) in 2024
Figure 65. South America VEGF Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 66. Middle East and Africa VEGF Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 67. GCC Countries VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 68. Israel VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 69. Egypt VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 70. South Africa VEGF Targeted Therapy Revenue (2020-2025) & (US$ Million)
Figure 71. VEGF Targeted Therapy Industry Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232